Compare Cognizant Technology Solutions Corp (CTSH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Novartis AG — how do they compare? Cognizant Technology Solutions Corp trades at $58.6 (market cap $26.27B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 11.4× Cognizant Technology Solutions Corp's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| CTSH | NVS | |
|---|---|---|
Market Cap | $26.27B | $298.18B |
Sector | Technology | Health |
52-Week High | $86.70 | $168.62 |
52-Week Low | $38.73 | $119.31 |
Enterprise Value | $27.31B | $339.50B |
Dividend Yield | 2.26% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $57.67, up 1.37% with a bullish technical signal. Recent Q2 2026 earnings missed EPS estimates at $1.37 versus $1.38 expected, though revenues beat. The company maintains solid fundamentals with a P/E of 12.37 and ROE of 14.92%, supported by strong cash flow from operations of $2.88B in 2025. AI initiatives, including the new EMEA AI Unit, highlight growth efforts amid cautious client spending.
Outlook is mixed: valuation appears attractive with upside to the $59.92 consensus target, but risks include macroeconomic pressures on IT spending and competitive disruption from AI. Earnings consistency and AI adoption execution are critical for sustained gains.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
